Vicore Pharma Holding AB

Bokslutskommunikéer

Visar 1 grupper

  1. Bokslutskommuniké Q4 2025

    ENSV
    →

    Financial Performance

    • Revenue for the year ended December 31, 2025, was SEK 3.8 million (2024: SEK 109.4 million).
    • Operating loss for the year ended December 31, 2025, was SEK 452.4 million (2024: SEK 194.2 million).
    • Loss for the period was SEK 477.5 million (2024: SEK 168.6 million).
    • Loss per share, before and after dilution, was SEK 1.99 (2024: SEK 1.23).
    • Cash,…

    Öppna rapport